- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Blue
Recent news which mentions Blue
From InvestorPlace
2 Stocks That Could Double Your Money in 2023
January 07, 2023
From Motley Fool
Newly Approved Drugs In US Command Over $200,000 On An Average
January 05, 2023
From Benzinga
From Motley Fool
After Doubling in the Past 6 Months, Is This Stock a Buy?
December 24, 2022
From Motley Fool
FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol
December 19, 2022
Tickers
BLUE
From Benzinga
Tickers
BLUE
From InvestorPlace
Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting
December 13, 2022
From Benzinga
2 Risky Stocks That Could Soar in 2023
December 06, 2022
From Motley Fool
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022
From Benzinga
From Benzinga
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
From Motley Fool
2 Growth Stocks That Could Double in 2023
November 17, 2022
From Motley Fool
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
November 08, 2022
From Benzinga
From Benzinga
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
October 27, 2022
From Motley Fool
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
October 25, 2022
From Benzinga
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
October 18, 2022
From Motley Fool
Bluebird Bio Offers World's Most Expensive Drugs, But Uncertainty Looms Over Its Financial Future
October 03, 2022
From Benzinga
From Benzinga
From Benzinga
So You Want a Career in Finance?
October 01, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.